MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
about
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testingClonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.Heterogeneity of tumor cells in terms of cancer-initiating cells.Current options to manage Waldenström's macroglobulinemia.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.Waldenstrom's Macroglobulinemia: An Update.Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.The role of G protein-coupled receptors in lymphoid malignancies.Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.MYD88 L265P mutation in cutaneous involvement by Waldenström macroglobulinemia.Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.B-cell lymphomas with discordance between pathological features and clinical behavior.Issues in diagnosis of small B cell lymphoid neoplasms involving the bone marrow and peripheral blood. Report on the Bone Marrow Workshop of the XVIIth meeting of the European Association for Haematopathology and the Society for Hematopathology.Preference of Genetic Diagnosis of CXCR4 Mutation Compared with Clinical Diagnosis of WHIM Syndrome
P2860
Q26784600-80D254C9-A381-458D-9C44-099BF444CABFQ33617237-507E8CBE-8C69-4A5A-A1C3-AC3B99699CE3Q33729711-F47EB600-557F-4D9E-B60C-966A08384D26Q36920426-E92657CD-8299-4A15-A4E9-0A1ED82929BBQ37318677-95C59F6D-C933-44F6-98BF-F0F0B039D909Q37499211-64F3FB95-BF72-49E9-AAF0-B5B9183FF3EBQ37725561-0D0376E5-2B9C-4865-BAA0-167AF4F8142EQ38594789-D75CE386-6F08-4C0F-90A4-BBCABE75B6AEQ38663689-F03CB5E0-73D5-43A2-822C-EE809024757FQ38760522-9EA3FFA5-362D-46BE-A8E3-939310ECD038Q38774535-B537CFFE-6582-4A1A-98E3-FEEF52092C37Q38839148-0B090C0B-A9B1-488F-B507-C8A449E64C6BQ39132578-15F3AA45-390A-4720-9D12-66BE0962BE02Q39358109-47D38659-7AA5-424F-921B-D3362D57725DQ39406673-158E19F6-9E0B-43DD-B210-50DFEA12F828Q47140051-391392FB-9D44-4B92-AA6C-8E24D8C017E5Q47736653-171A509F-E0F8-4BC5-96B1-9A4B1DAADB8AQ47737291-02565CFD-9FAF-4547-A0EE-DE454F69BB44Q47960121-D2A4F86D-B061-42C3-A324-D0F4418D3FF9Q48155069-893996E9-F51A-4909-B555-41FD954CD612Q48172125-C60FECC7-9E81-4991-9B81-F5A93DBA29BCQ48334384-05FD9F13-C1CA-4447-9077-EA954E106935Q51329192-FAA5F31B-B710-4E02-89C5-3DD5FC3841B2Q52863282-48933B7F-71A4-4C3D-84CB-8DA6C2281629Q52868118-C4B3B25D-1E89-478F-96A6-22DA2CC43994Q58196622-226C177F-A695-48D7-861D-FE46E5D75946
P2860
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MYD88 L265P and CXCR4 mutation ...... es with high disease activity.
@en
type
label
MYD88 L265P and CXCR4 mutation ...... es with high disease activity.
@en
prefLabel
MYD88 L265P and CXCR4 mutation ...... es with high disease activity.
@en
P2093
P2860
P356
P1476
MYD88 L265P and CXCR4 mutation ...... es with high disease activity.
@en
P2093
Birgit Federmann
Irina Bonzheim
Janine Schmidt
Julia Steinhilber
Leticia Quintanilla-Martinez
Natalie Schindler
P2860
P304
P356
10.1111/BJH.13361
P407
P577
2015-03-29T00:00:00Z